These findings suggest that Andrographolide not only modulates VAT-specific metabolism but also exerts beneficial effects on whole-body glucose homeostasis in APP/PS1 mice with obesity, thereby contributing to an overall improvement in metabolic health. The gene discussed is APP; the disease is obesity disorder.